Evidence map›Paper›PMID 35194609›Full record

ArticlebioRxiv : the preprint server for biology2022

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions.

Yang Liu, Xianwen Zhang, Jianying Liu, Hongjie Xia, Jing Zou, Antonio E Muruato, Sivakumar Periasamy, Jessica A Plante, Nathen E Bopp, Chaitanya Kurhade and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Yang LiuDepartment of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston TX, USA.
Xianwen ZhangDepartment of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston TX, USA.
Jianying LiuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Hongjie XiaDepartment of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston TX, USA.
Jing ZouDepartment of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston TX, USA.
Antonio E MuruatoDepartment of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston TX, USA.
Sivakumar PeriasamyDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Jessica A PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Nathen E BoppDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Chaitanya KurhadeDepartment of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston TX, USA.
Alexander BukreyevDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Ping RenInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Tian WangDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Kenneth S PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Xuping XieDepartment of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston TX, USA.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston TX, USA.
The University of Texas Medical Branch at Galveston · USGalveston College · US

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
Unlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S · 2012 to 2021
$36.6M
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
Revolutionary Eilat-based Chikungunya Vaccine VectorR01AI127744 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WANG, TIAN · 2017 to 2021
$3.5M
Regulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1M
Systems Based Analysis of Host Factors that Contribute to Aging PathogenesisR00AG049092 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2017 to 2019
$736k
Role of Pellino-1 in COVID-19 diseasesR21AI140569 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WANG, TIAN · 2019 to 2020
$660k
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health ThreatsR43AI145617 · NIAID · PLEX PHARMACEUTICALS, INC. · PI REMACLE, ALBERT, THOTA, SAMBAIAH · 2020 to 2021
$600k
NCATS NIH HHS UL1 TR001439NIAID NIH HHS HHSN272201600013CNIAID NIH HHS R01 AI127744NIAID NIH HHS R01 AI134907NIAID NIH HHS R21 AI140569NIAID NIH HHS R24 AI120942NIAID NIH HHS R43 AI145617NIAID NIH HHS U19 AI100625NIAID NIH HHS U19 AI142790NIA NIH HHS R00 AG049092
6 · The paper itself

Abstract

We report a live-attenuated SARS-CoV-2 vaccine candidate with (i) re-engineered viral transcriptional regulator sequences and (ii) deleted open-reading-frames (ORF) 3, 6, 7, and 8 (Δ3678). The Δ3678 virus replicates about 7,500-fold lower than wild-type SARS-CoV-2 on primary human airway cultures, but restores its replication on interferon-deficient Vero-E6 cells that are approved for vaccine production. The Δ3678 virus is highly attenuated in both hamster and K18-hACE2 mouse models. A single-dose immunization of the Δ3678 virus protects hamsters from wild-type virus challenge and transmission. Among the deleted ORFs in the Δ3678 virus, ORF3a accounts for the most attenuation through antagonizing STAT1 phosphorylation during type-I interferon signaling. We also developed an mNeonGreen reporter Δ3678 virus for high-throughput neutralization and antiviral testing. Altogether, the results suggest that Δ3678 SARS-CoV-2 may serve as a live-attenuated vaccine candidate and a research tool for potential biosafety level-2 use.

Identifiers

PMID35194609
PMCPMC8863145
OpenAlexW4213351485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.